Estrogen-progestin increases breast cancer risk
Stephens, M.B.
Journal of Family Practice 49(4): 301-302
2000
ISSN/ISBN: 0094-3509 PMID: 10778832 Document Number: 513389
Document emailed within 1 workday
Related Documents
Glaser, A.N. 2000: Estrogen-progestin replacement and risk of breast cancer JAMA 284(6): 692; Author Reply 693-4Chlebowski, R.T.; Rohan, T.E.; Manson, J.E.; Aragaki, A.K.; Kaunitz, A.; Stefanick, M.L.; Simon, M.S.; Johnson, K.C.; Wactawski-Wende, J.; O'Sullivan, M.J.; Adams-Campbell, L.L.; Nassir, R.; Lessin, L.S.; Prentice, R.L. 2015: Breast Cancer After use of Estrogen Plus Progestin and Estrogen Alone: Analyses of Data from 2 Women's Health Initiative Randomized Clinical Trials JAMA Oncology 1(3): 296-305
Persson, I. 1996: Cancer risk in women receiving estrogen-progestin replacement therapy Maturitas 23(Suppl): S37-S45
Nachtigall, M.J.; Smilen, S.W.; Nachtigall, R.D.; Nachtigall, R.H.; Nachtigall, L.E. 1992: Incidence of breast cancer in a 22-year study of women receiving estrogen-progestin replacement therapy Obstetrics and Gynecology 80(5): 827-830
Grant, E.C.G. 2017: Lifetime cancer risk with progestin and estrogen oral contraceptives and hormone therapy American Journal of Obstetrics and Gynecology 217(2): 232-233
Schildkraut, J.M.; Calingaert, B.; Marchbanks, P.A.; Moorman, P.G.; Rodriguez, G.C. 2002: Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk Journal of the National Cancer Institute 94(1): 32-38
Faber, M.T.; Jensen, A.; Frederiksen, K.; Glud, E.; Høgdall, E.; Høgdall, C.; Blaakaer, J.; Kjaer, S.K. 2013: Oral contraceptive use and impact of cumulative intake of estrogen and progestin on risk of ovarian cancer Cancer Causes and Control: Ccc 24(12): 2197-2206
Horwitz, K.B. 1985: The antiprogestin RU38 486: receptor-mediated progestin versus antiprogestin actions screened in estrogen-insensitive T47Dco human breast cancer cells Endocrinology 116(6): 2236-2245
Schlesselman, J.J.; Stadel, B.V.; Murray, P.; Lai, S.H. 1987: Breast cancer risk in relation to type of estrogen contained in oral contraceptives Contraception 36(6): 595-613
Santen, R.J.; Pinkerton, J.; McCartney, C.; Petroni, G.R. 2001: Risk of breast cancer with progestins in combination with estrogen as hormone replacement therapy Journal of Clinical Endocrinology and Metabolism 86(1): 16-23
Porcelli, A.; Calleri, L.; Gallello, D.; Taccani, C.; Surico, N. 1997: Estrogen-progestin contraception and biohumoral response of new markers of the atheroma risk. Behavior of lipoprotein(a) and apolipoproteins a and B Minerva Ginecologica 49(3): 63-66
Magnusson, C.; Weiderpass, E. 2001: Hormone therapy in climacteric. Different effects of estrogen and gestagen on the risk of breast and endometrial cancer Lakartidningen 98(5): 418-421
2002: New SBU-report on estrogen replacement therapy in climacteric. Moderate risk of breast cancer after long-term use Lakartidningen 99(28-29): 3031-3034
Cheewadhanaraks, S.; Choksuchat, C.; Wattanakumtornkul, S. 2013: Estrogen plus progestin versus estrogen after definitive surgery for endometriosis: a study of pain recurrence Journal of the Medical Association of Thailand 96(8): 881-887
Casper, R.F. 2017: Progestin-only pills may be a better first-line treatment for endometriosis than combined estrogen-progestin contraceptive pills Fertility and Sterility 107(3): 533-536
Denis, C. 1993: Estrogen-progestin contraception. Disadvantages of estrogen reduction Contraception Fertilite Sexualite 21(6): 481-488
Cohen, J. 1993: Estrogen-progestin contraception. Advantages of estrogen reduction Contraception Fertilite Sexualite 21(6): 489-494
Knopp, R.H.; Walden, C.E.; Wahl, P.W.; Hoover, J.J.; Warnick, G.R.; Albers, J.J.; Ogilvie, J.T.; Hazzard, W.R. 1981: Oral contraceptive and postmenopausal estrogen effects on lipoprotein triglyceride and cholesterol in an adult female population: relationships to estrogen and progestin potency Journal of Clinical Endocrinology and Metabolism 53(6): 1123-1132
Tominaga, T.; Abe, O.; Izuo, M.; Isono, K.; Enomoto, K.; Nishi, M.; Fukami, A.; Muto, T.; Morioka, Y.; Watanabe, H. 1993: Correlations between estrogen receptor and prognostic factors of patients with breast cancer. the Kanto Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer, Japan Gan to Kagaku Ryoho. Cancer and ChemoTherapy 20(14): 2171-2176
Lipkus, I.M.; Iden, D.; Terrenoire, J.; Feaganes, J.R. 1999: Relationships among breast cancer concern, risk perceptions, and interest in genetic testing for breast cancer susceptibility among African-American women with and without a family history of breast cancer Cancer Epidemiology Biomarkers and Prevention: a Publication of the American Association for Cancer Research Cosponsored by the American Society of Preventive Oncology 8(6): 533-539